MicroRNAs (miRNAs) are thought to control tumor metastasis through direct interactions with target genes. Thyroid hormone (T 3 ) and its receptor (TR) are involved in cell growth and cancer progression. However, the issue of whether miRNAs participate in T 3 /TRmediated tumor migration is yet to be established. In the current study, we demonstrated that T 3 /TR negatively regulates mature miR-17 transcript expression, both in vitro and in vivo. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays localized the regions responding to TR-mediated repression to positions À 2234/ À 2000 of the miR-17 promoter sequence. Overexpression of miR-17 markedly inhibited cell migration and invasion in vitro and in vivo, mediated via suppression of matrix metalloproteinases (MMP)-3. Moreover, p-AKT expression was increased in miR-17-knockdown cells that led to enhanced cell invasion, which was blocked by LY294002. Notably, low miR-17 expression was evident in highly metastatic cells. The cell migration ability was increased by T 3 , but partially reduced upon miR-17 overexpression. Notably, TRa1 was frequently upregulated in hepatocellular carcinoma (HCC) samples and associated with low overall survival (P ¼ 0.023). miR-17 expression was significantly negatively associated with TRa1 (P ¼ 0.033) and MMP3 (P ¼ 0.043) in HCC specimens. Data from our study suggest that T 3 /TR, miR-17, p-AKT and MMP3 activities are interlinked in the regulation of cancer cell metastasis.
INTRODUCTION
Thyroid hormone (3, 3 0 ,5-triiodo-L-thyronine; T 3 ) interacts with thyroid hormone receptors (TRs) to regulate cell homeostasis, growth, development and differentiation. 1 Human TRs are encoded by TRa1 and TRb1 genes located on chromosomes 17 and 3, respectively. 2 These receptors function in a liganddependent manner via binding to thyroid hormone response elements (TREs) of target gene promoter regions. 3 The v-erbA oncogene product is reported to be a nuclear protein that antagonizes TR function through competition for liganddependent transcriptional activity protein. 4 A number of studies to date have revealed an oncogenic role of T 3 /TR in tumor progression, including the pituitary, 5 breast 6 and prostate 7 cancers and glioma. 8 MicroRNAs (miRNAs) are a class of non-coding RNA genes producing 22-nucleotide functional RNA molecules that have critical roles in the regulation of target genes via binding to complementary regions of messenger transcripts to suppress their translation or regulate mRNA degradation. 9 Earlier studies have revealed significant correlations between miRNA gene expression and human tumorigenesis. Genes encoding miRNAs are frequently located at fragile sites, such as loss of heterozygosity or regions of amplification. [10] [11] [12] A human miR-17 cluster, located on the chromosome 13q31, undergoes loss of heterozygosity in hepatocellular carcinoma (HCC). 13 Tumor cells invade distant organs through interactions with the extracellular matrix. Several matrix metalloproteinases (MMPs) responsible for extracellular matrix degradation have been identified to date. Among these, MMP3 (stromelysin-1) degrades collagenous and non-collagenous matrix components, such as the fibronectin and laminin. MMP3 expression is upregulated in several cancers, including head-andneck carcinoma, 14 gastric cancer, 15 pancreatic cancer 16 and HCC. 17 In this study, we hypothesized that deregulation of specific miRNAs and target gene expression mediated by T 3 /TR is involved in cancer progression. Our experiments showed that T 3 downregulates miR-17 expression in HepG2-TR-expressing cells, both in vitro and in vivo. Negative TREs were identified within the miR-17 promoter region. MMP3 appeared to be directly regulated by miR-17. Moreover, miR-17 reduced cell migration and invasion through modulation of both MMP3 and p-AKT. Results obtained with an animal model further supported a suppressor role of miR-17 in metastasis. T 3 /TR promoted cell migration through downregulation of miR-17. These data collectively support a novel metastatic pathway involving the concerted activities of T 3 /TR, miR-17, p-AKT and MMP3 in hepatoma cells.
RESULTS

miR-17 is downregulated by the thyroid hormone
To determine whether miR-17 is regulated by T 3 /TR, TRa1-and TRb1-expressing HepG2 cell lines were established, with HepG2-neo as the negative control (data not shown). Cells were treated with T 3 (1-10 nM) for 24-72 h or left untreated, and mature miR-17 expression was measured using qRT-PCR. Expression of miR-17 was 15% to 70% lower after incubation of HepG2-TRa1 and HepG2-TRb1 with T 3 for 24-72 h, respectively ( Figure 1a , left and middle panels). In contrast, miR-17 was only marginally regulated by T 3 /TR in HepG2-neo cells devoid of TR expression (Figure 1a , right panel). For each experiment, miR-17 expression levels were normalized to that of internal control miR-16, which is not Figure 1 . miR-17 is downregulated by T 3 /TR. HepG2-TR cells were treated with 0-10 nM T 3 for 24-72 h, and miR-17 (a) and pri-miR-17 (b) levels were measured using qRT-PCR. miR-16 and RiboL35A were used as loading controls, respectively. Data are presented as means±s.d. of three independent experiments (*Po0.05; **Po0.01 vs 24 h (0 nM)). (c) HepG2-TRa1 cells were co-transfected with the miR-17 promoter and b-galactosidase plasmids. Cells were incubated for 24 h in the presence or absence of 10 nM T 3 , and luciferase activity was determined. (d) For the ChIP assay, HepG2-TRa1 cells were treated with T 3 and harvested after 24 h. Sonicated lysates were immunoprecipitated with antibodies against MOPC21 (IgG), C4 (TR) or RXR, respectively. regulated by T 3 /TR. Similar results were normalized to U6 smallnuclear RNA (Supplementary Figure S1) . Further qRT-PCR analysis showed that the miR-17 primary transcript, pri-miR-17, is significantly downregulated by T 3 /TR in HepG2-TR cells but not in HepG2-neo cells treated with T 3 (Figure 1b) . Our results indicate time-and dose-dependent effects of T 3 in vitro.
T 3 -dependent repression of the miR-17 promoter via interactions with TR Promoter activity analysis was performed to determine whether miR-17 is regulated by T 3 at the transcriptional level. The specific consensus sequence of the negative TREs (nTREs) remained unclear. Thyroid-stimulating hormone (TSH) and Nm23-H1 genes are both downregulated by T 3 . 18, 19 Accordingly, the nTRE sequences of genes bound by TRs were used as a reference, as presented in Figure 1c . The luciferase activity was decreased by about 40% in fragments I, V and VII in the presence of T 3 , suggesting that the potential nTRE is located within fragment VII. Consistent with this theory, the repression activity was alleviated upon deletion of the putative nTRE in fragment VII (Figure 1c , fragment VIII). TR binding to the promoter fragment VII of miR-17 in vivo was confirmed using the ChIP assay. TRa1 and RXRa bound to the miR-17 promoter fragment pulled down with the C4 and RXRa antibodies, respectively, but not the mopc21 (Immunoglobulin) antibody (Figure 1d) . A signal was detected with the positive control (TRAIL) 20 but not with the negative control (GAPDH). Our results clearly indicate that TR binds to the miR-17 promoter in vivo.
miR-17 controls cell migration and invasion via modulation of p-AKT activity To establish the biological function of miR-17, qRT-PCR was used to determine the miR-17 expression patterns in HCC cell lines. HCC cell lines expressing low (Mahlavu) and high (SK-Hep1) levels of miR-17 were used (data not shown). Cells with stable overexpression (miR-17) or knockdown (anti-17#1 and anti-17#2) of miR-17 were generated, and expression was confirmed with qRT-PCR (Figures 2a and b) . The proliferative properties of control and miR-17 stable cells were comparable (data not shown). However, cell migration and invasion abilities were inhibited in miR-17-overexpressing Mahlavu cells (Figure 2c ), whereas cell motility and invasiveness were promoted in SK-Hep1 cells depleted of endogenous miR-17 ( Figure 2d ). Expression of p-AKT was decreased in cells overexpressing miR-17 and, conversely, increased in miR-17-knockdown cells (Figure 2e ). To further explore whether the suppressive effect of miR-17 on cell invasion is mediated via p-AKT activity, the invasion assay was performed on cells treated with or without LY294002, a p-AKT inhibitor. Inhibition of p-AKT activity with LY294002 led to the attenuation of cell invasion in miR-17-knockdown cells (Figure 2f ). Importantly, our experiments showed that p-AKT is upregulated by T 3 /TR signaling (Supplementary Figure S2) , reported to promote cell migration and invasion. 21 These findings support a regulatory pathway involving associations between T 3 /TR, miR-17 and p-AKT in cancer cell metastasis.
MMP3 is a miR-17 target gene upregulated by T 3 /TR To directly explore the effect of the T 3 /miR-17 axis in hepatoma cells, specific target genes of miR-17 upregulated by T 3 were selected for further study. TargetScan (online database) and T 3 -regulating complementary DNA (cDNA) microarray (data not shown) were available for comparison. MMP3 was subsequently examined as a candidate miR-17 target gene. The luciferase activity of wild-type MMP3 3 0 -UTR was inhibited by miR-17. This suppressive effect was abolished upon mutation of MMP3 3 0 -UTR (Figure 3a, left panel) . The miR-17 sensor reporter plasmid was used as a positive control (Figure 3a , right panel). MMP3 mRNA expression was decreased in miR-17-overexpressing Mahlavu cells ( Figure 3b ). Further, pro-and active MMP3 protein levels were decreased and increased in miR-17-overexpressing and -knockdown cells, respectively ( Figure 3c ). Fibronectin suppression by miR-17, confirmed previously by Shan et al., 22 was used as positive control in our experiment. MMP3 mRNA and protein levels were both repressed by miR-17, indicating that MMP3 is a direct target gene of miR-17 in hepatoma cells. As miR-17 is downregulated by T 3 /TR signaling, the effects of T 3 /TR on MMP3 were further confirmed in HepG2-TRa1 cells. Specifically, HepG2-TRa1 cells were incubated in the presence or absence of T 3 for 24-48 h, and MMP3 mRNA and protein expressions were measured using qRT-PCR and western blot, respectively. Both MMP3 mRNA and protein levels were upregulated by T 3 in HepG2-TRa1 but not HepG2-neo cells (Figures 3d and e) . To determine the effects of MMP3 on cell migration and invasion, stable knockdown of MMP3 in Mahlavu cells was performed via lentivirus infection. Knockdown efficiency was confirmed using western blot (Supplementary Figure S3) . Loss of MMP3 expression reduced cell migration and invasion ability (Figure 3f ), similar to that observed in the presence of miR-17. miR-17 is downregulated in a highly metastatic cell line To confirm the tumor suppressor role of miR-17 in cancer metastasis, in vitro transwell and in vivo SCID mice models were used to select highly metastatic cell populations (a SK-Hep-1-derived cell line, designated SK-R3-TW3). The invasion ability of SK-R3-TW3 was higher than that of SK-Hep1 cells (unpublished observations). Mature miR-17 and MMP3 mRNA expression levels were measured using qRT-PCR in these cell lines. Mature miR-17 was significantly lower, whereas MMP3 mRNA expression was higher in SK-R3-TW3 than SK-Hep1 cells (Figure 4a ). MMP3 and p-AKT protein levels were highly abundant in SK-R3-TW3 cells ( Figure 4b ). Subsequently, miR-17-overexpressing (miR-17#1 and miR-17#2) SK-R3-TW3 cells were generated, and a transwell assay was performed. The efficiency of miR-17 overexpression was tested using qRT-PCR (Supplementary Figure S4) . Notably, cell migration and invasion abilities were inhibited by miR-17 in SK-R3-TW3 cells (Figure 4c ). To further explore the effect of miR-17 on metastasis in vivo, SCID mice were injected with control (LacZ) or miR-17-overexpressing (miR-17#2) SK-R3-TW3 cells. SCID mice with miR-17-overexpressing cell xenografts developed fewer metastatic foci in lungs, as evident from hematoxylin and eosin (H&E) staining. The metastatic index was decreased by 70% in miR-17#2 cells, compared with control cells (Figure 4d , right panel). Moreover, MMP3 protein, observed as a dark-brown color in immunohistochemical staining, displayed markedly lower expression in SK-R3-TW3-miR-17#2 than SK-R3-TW3-lacZ lung tumors (Figure 4d, left panel) . Similar results were observed with western blot analysis (Figure 4e ). Clearly, miR-17 is expressed at a reduced level in highly metastatic cell lines and has a suppressor role against metastasis in vivo.
Overexpression of miR-17 blocks MMP3-mediated T 3 promotion of cell motility MMP3 is a known target gene of miR-17. To determine whether overexpression of MMP3 rescues the suppressive phenotype in cells overexpressing miR-17, MMP3 was expressed using a plasmid construct lacking 3 0 -UTR in miR-17-expressing Mahlavu cells. MMP3 expression in LacZ and miR-17-expressing cells was detected via western blot analysis (Figure 5a ). Indeed, miR-17-reduced cell migration and invasion were partially rescued by the introduction of MMP3 (Figure 5b ). To elucidate whether T 3 /TR promotion of cell migration ability is mediated via miR-17 downregulation, miR-17-expressing HepG2-TRa1 cells were generated and the transwell migration was assay performed in the presence or absence of T 3 . T 3 treatment enhanced cell migration in HepG2-TRa1-LacZ cells, compared with that in the absence of T 3 . However, this effect was partially repressed after miR-17 overexpression in the presence of T 3 ( Figure 5c ). To further confirm this effect, miR-17-expressing Mahlavu cells were infected with Adenovirus-TRa1 (Ad-TRa1), and cell migration was examined in the presence or absence of T 3 . Cell migration mediated by T 3 was partially reduced by miR-17 ( Figure 5d ). These characteristics were similar to those observed upon miR-17 overexpression in the HepG2-TRa1 phenotype. Further, overexpression of miR-17 in T 3 conditions reduced p-AKT and MMP3 expression, compared with control ( Figure 5e , lane 2 vs 4). Our findings collectively suggest that miR-17 and MMP3 have important roles in regulation of T 3 /TRinduced cell migration. miR-17 is downregulated by T 3 in hyperthyroidal rats and negatively correlated with TRa1 and MMP3 in a subset of human HCC To establish whether miR-17 is similarly regulated by T 3 /TR in vivo, experiments were performed on hyper-(Tx þ T 3 ), hypo-(Tx) and euthyroid (sham) rats. Total RNA was extracted from livers, and miR-17 expression was detected using qRT-PCR. Mature miR-17 was decreased by about 40% in hyperthyroid rats, compared with the hypothyroid group (Figure 6a) . To analyze the impact of TRa1 expression on clinical outcome, expression of TRa1 was measured using qRT-PCR in 76 pairs of HCC specimens. TRa1 mRNA expression was increased in cancerous tissue, compared with noncancerous adjacent tissue, in B84% (64/76) cases. Patients were dichotomized into two groups based on indicate that miR-17 downregulation by T 3 /TR in vivo is inversely correlated with expression of TRa1 in a subset of hepatoma specimens.
DISCUSSION
In this study, we have identified miR-17 as a novel target gene for T 3 /TR-mediated transcriptional repression for the first time. This conclusion is based on the following observations: (1) T 3 treatment reduced mature miR-17 and pri-miR-17 expression in cells containing TRs (HepG2-TRa1 and HepG2-TRb1), but had no effect on HepG2-neo expressing barely detectable levels of TR. (2) The ChIP assay revealed the localization of potential nTREs on promoter regions at positions À 2234/ À 2000. (3) The regulatory effect was further confirmed in thyroidectomized rat models. miR-17 expression was significantly decreased in hyperthyroid, compared with hypothyroid groups.
The potential function of miR-17 in cancer progression is controversial. miR-17 is proposed to function as either an oncomiR or tumor suppressor, depending on the cell type. Li et al. 23 reported that overexpression of miR-17 in a breast cancer cell line promotes invasion ability by targeting HMG box-containing protein 1 (HBP1) to activate the oncogenic activity of b-catenin. Conversely, Yu and colleagues 24 demonstrated that miR-17 has a tumor suppressor role in breast cancer cell lines, inhibiting proliferation and colony formation via suppression of cyclin D1. In another report, miR-17 was shown to be expressed at higher levels in noninvasive breast cancer cell lines than their highly invasive counterparts. Moreover, miR-17 reduced cell invasion ability through heterotypic signaling by altering cytokeratin-8, a-enolase and interleukin-8 (IL-8) levels. 25 Additionally, both IL-8 and cyclin D1 protein levels were decreased in miR-17-overexpressing cells and upregulated by T 3 /TR (Supplementary Figure S5a and b) . Expression patterns of these genes, including IL-8 and cyclin D1, are consistent with the findings of Yu and colleagues. 24, 25 Previously, Yang et al. 26 demonstrated that miR-17 is upregulated in metastatic HCC patients and promotes cell migration, invasion and proliferation through the heat shock protein 27 pathway in Huh7 cells, contradictory to our findings. Here, we further established a highly metastatic cell lines (SK-R3-TW3) by in vitro transwell and in vivo SCID mice models to support the tumor suppressor activity of miR-17 in cancer metastasis. Our data clearly showed that miR-17 is expressed at lower levels in SK-R3-TW3, compared with SK-Hep1 cells. We demonstrated that miR-17 has a tumor suppressor role by inhibiting migration and invasion of Mahlavu and SK-R3-TW3 cells. Similar results were observed in oral squamous cell carcinoma (OSCC). 27 Chang et al. 27 established a more-aggressive cell line, TW2.6 MS-10, by transwell selection from low migration parental TW2.6 cells. miR-17, miR-19b, miR-20a and miR-92a are expressed at lower levels in TW2.6 MS-10, compared with TW2.6 cells. Further, overexpression of miR-17 or miR-20a decrease cell migration in OSCC cell lines.
Previous studies have documented that MMP3 28 and p-AKT 29 trigger cell migration and invasion. Zhang et al. 28 demonstrated that overexpression of cyclophilin A (CypA) belonging to the peptidyl prolyl isomerase family in SK-Hep1 promotes cell invasion ability mediated by MMP3. Interestingly, both MMP3 and p-AKT were upregulated by T 3 /TR in our experiments and involved in miR-17 regulation of cell invasion ability. Further, T 3 /TR promotion of cell migration was partially suppressed by restoration of miR-17 expression in HepG2-TRa1 and Mahlavu-TRa1 cells. Overall, our results support the theory that the T 3 /miR-17 axis regulates MMP3 expression and p-AKT activity, contributing to cell migration and invasion.
Consistent with our findings, T 3 /TR has been shown to promote migration and invasion ability in HCC cell lines by regulating the expression of several genes, including Furin, 21 cathepsin H (CTSH), 30 plasminogen activator inhibitor-1 (PAI-1) 31 and tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL). 20 Yet another report supports an oncogenic role for T 3 /TR in human cancer. Kress and co-workers 32 demonstrated that TRa1 overexpression and Wnt pathway activation promote colorectal cancer formation, whereby TRa1 stimulates tumorigenesis in APC þ /1638N mice with a Wnt-activated genetic background. An oncogenic role of T 3 /TR in cancer metastasis has been postulated in a subset of HCC. In this study, TRa1 gene was highly expressed in a subset of HCC and associated with low overall survival. Moreover, our experiments showed that miR-17 is inversely correlated with TRa1 and MMP3 levels. These findings demonstrate that miR-17 downregulation in a subset hepatoma may be TR dependent and suggests that this downregulation has an important role in hepatoma progression. In conclusion, our findings provide evidence of a novel pathway interlinking T 3 /TR, miR-17 and MMP3 that regulates motility and invasion of hepatoma cells.
MATERIALS AND METHODS
Cell culture
HepG2, Mahlavu, SK-Hep1 and SK-R3-TW3 cell lines were cultured in DMEM containing 10% (v/v) FBS. Stable cell lines, including HepG2-TRa1, HepG2-TRb1 and HepG2-neo, were cultured in DMEM containing 10% (v/v) FBS with G418. Serum was depleted of T 3 , as described previously. 33 Cells were cultured at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 .
Quantitative reverse transcription-RT-PCR
To quantify mRNA transcripts, total RNA was extracted from cells using the TRIzol reagent kit (Life Technology Inc., Carlsbad, CA, USA). RNA was converted to cDNA using a reverse transcriptase (Life Technologies). The qRT-PCR was conducted in a 15 ml reaction mixture containing forward and reverse primers, and 1X SYBR Green mix (Applied Biosystems, Carlsbad, CA, USA). miRNA quantification has been described previously. 34 Briefly, 10 ml reaction mixture containing miRNA-specific stem-loop RT primers, dNTP, reverse transcriptase and 1 mg total RNA were used for the RT reaction. The qRT-PCR was conducted in a 10 ml reaction mixture containing miRNAspecific forward primer, universal reverse primer and 1X SYBR Green mix (Applied Biosystems). The sequences of primer in qRT-PCR were listed in Supplementary Table S1 .
Cloning of the miR-17 promoter and promoter activity analysis Fragments of the miR-17 promoter were amplified via PCR according to the published nucleotide sequence and cloned into pGL3-TK-basic vector (the first nucleotide of the precursor form of miR-17 was defined as þ 1). The detailed promoter activity analysis has been described previously. 35 
Chromatin immunoprecipitation assay
The ChIP assay was performed to detect the interactions between TR and TREs on the miR-17 promoter regions, as described in a previous report. 35 The following primers were listed in Supplementary Table S1 .
Immunoblotting analysis
Total cell lysates and conditioned media were prepared and protein concentrations were determined by the Bradford assay kit (Pierce Biotechnology, Rockford, IL, USA). The detailed immunoblotting analysis has been described previously. 30 A rabbit anti-human antibody directed against MMP3 was purchased from BD Biosciences (San Jose, CA, USA). Rabbit anti-human antibodies directed against AKT1 and phsophorylated-AKT (Ser473) were purchased from Epitomics (Burlingame, CA, USA). A mouse anti-human antibody b-catenin and a rabbit anti-human antibody Fibronectin were purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). A mouse anti-human antibody GAPDH was purchased from Merck Millipore (Billerica, MA, USA). Mouse antihuman antibodies IL-8 and c-Myc were purchased from R&D Systems (Minneapolis, MN, USA) and GeneTex (Irvine, CA, USA), respectively. A C4 antibody (a gift from S-Y Cheng, National Cancer Institute) against TRa1 and TRb1 was used in this study. Band intensities were calculated using Image Gauge software (Fuji Film, Tokyo, Japan).
Immunohistochemical staining
The detailed immunohistochemical staining protocol has been described previously. 36 Briefly, primary MMP3 antibody was used at a 1:100 dilution, along with the horseradish peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz). Signals were detected using the EnVision kit (DAKO, Carpinteria, CA, USA). MMP3-positive staining was visualized as a brown color. 
Migration and Invasion assay
Cells in serum-free DMEM were seeded onto the upper chambers of Transwell filter devices and DMEM containing 20% FBS added to the lower chambers, as decribed previously. 37 Luciferase reporter assay
The full-length 3 0 -UTR of human MMP3 (MMP3 3 0 -UTR wt) was amplified by PCR from cDNA and cloned at the SpeI and HindIII sites into pMIR-REPORT vector (Applied Biosystems). The putative miR-17 binding sites in MMP3 3 0 -UTR were mutated by PCR and validated by sequencing. pMiR-MMP3-3 0 -UTR wild-type (wt) and pMiR-MMP3-3 0 -UTR mutant (mut) were transfected into Mahlavu-miR-17-overexpressing and LacZ cells using TurboFect (Fermentas). After transfection for 24 h, luciferase activity was measured. A positive control constructs contain complete complementary mature miR-17-binding sequences (called miR-17-sensor).
Xenograft models of tumor progression and metastasis
Severe combined immunodeficient (SCID) mice were used to determine the invasive ability of miR-17-overexpressing SK-R3-TW3 cells. SK-R3-TW3-LacZ and SK-R3-TW3-miR-17#2 cells (5 Â 10 6 ) were injected intravenously. All animals were killed on the fifth week after tumor inoculation, whereupon livers and lungs were removed. All animal experiments were performed according to the United States National Institutes of Health guidelines and the Chang Gang Institutional Animal Care and Use Committee Guide for Care and Use of Laboratory animals.
Adenovirus-TRa1 generation
TRa1 cDNA was cloned into the pAd-track CMV vector, as described previously. 38 Cells were infected with vector control or Ad-TRa1 for 24 h. Subsequently, cell migration assay was performed.
Thyroidectomy and HCC specimens Hypo (Tx), hyper (Tx þ T 3 ) and euthyroid (sham) rats were generated based on a previous report. 21 All animal experiments were performed according to the NIH and Chang Gang Institutional Animal Care guidelines. Additionally, 76 paired HCC samples obtained from Taiwan Liver Cancer Network (TLCN) were selected for the study. The protocol was reviewed with the approval of the Institutional Review Board (IRB, No: 98-0798B) of Chang-Gung Memorial Hospital. The basic clinical characterization of patients was presented in Supplementary Table S2 .
Statistical analysis
Statistical analysis was performed using SPSS version 15 (SPSS Inc., Chicago, IL, USA). One-way ANOVA was used to compare the results obtained for more than one treatment. Differences between two groups were analyzed with the Student's t-test. The cancer-specific overall survival with death as event was analyzed using log-rank test.
